NASDAQ:BIB

Proshares Ultra Nasdaq Biotechnology ETF News

etoro logo Buy BIB
*Your capital is at risk
$83.72
+1.06 (+1.29%)
At Close: Jun 15, 2026
The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that offic
As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt t

5 Best Leveraged ETFs of Last Week

09:47am, Monday, 14'th Jun 2021
We highlight a few leveraged ETF areas that won last week.
Capital Investment Advisors LLC raised its holdings in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 28.4% during the 2nd quarter, according to the company in its most recent Form 13F filing wi
Tower Research Capital LLC TRC cut its stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 95.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange
Biotechnology companies have many growth levers and are to be favored for their defensive qualities, in the context of the health and economic crisis.
While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.
Last week witnessed a tug-of-war between bulls and bears.
Nasdaq Stock Exchange President Nelson Griggs joins Yahoo Finance’s Seana Smith to discuss market operations amid the coronavirus and the outlook on IPOs.
Ladenburg Thalmann Financial Services Inc. lifted its position in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 500.0% in the fourth quarter, Holdings Channel reports. The institution

ING's Latest Economic Views And Forecasts

07:52pm, Monday, 16'th Mar 2020
Our gut feeling is that this will not be the last update. US: We are penciling in an 8.0% annualised 2Q20 GDP decline. Europe: Bund yields will likely continue
Shares of biotech Inovio Pharmaceuticals Inc. fell more than 20% Friday, as analysts weighed in on the company’s latest earnings and RBC downgraded the stock on valuation grounds.
The urgent need for a vaccine for coronavirus has sent biotech companies actively developing one, making biotechnology funds attractive.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE